Cargando…
Effect of Xuezhikang Therapy on Expression of Pulmonary Hypertension Related miR-638 in Patients With Low HDL-C Levels
Objective: Low plasma level of high-density lipoprotein cholesterol (HDL-C) associated with poor outcomes in several cardiovascular diseases, including pulmonary arterial hypertension (PAH). Regulation of miR-638 have been proved to be associated with PAH. The aim of this study was to evaluate the e...
Autores principales: | Cao, Ruihua, Sun, Tao, Xu, Ruyi, Zheng, Jin, Wang, Hao, Wang, Xiaona, Bai, Yongyi, Ye, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721165/ https://www.ncbi.nlm.nih.gov/pubmed/34987392 http://dx.doi.org/10.3389/fphar.2021.764046 |
Ejemplares similares
-
Xuezhikang Therapy Increases miR-33 Expression in Patients with Low HDL-C Levels
por: Cao, Ruihua, et al.
Publicado: (2014) -
MiR-638 acts as a tumor suppressor gene in gastric cancer
por: Shen, Yu, et al.
Publicado: (2017) -
Dysregulation of miR-638 in diabetic nephropathy and its role in inflammatory response
por: Lin, Mei, et al.
Publicado: (2021) -
Xuezhikang reduced arterial stiffness in patients with essential hypertension: a preliminary study
por: Zheng, J., et al.
Publicado: (2017) -
MiR-638 Repressed Vascular Smooth Muscle Cell Glycolysis by Targeting LDHA
por: Chen, Shiyuan, et al.
Publicado: (2019)